Curriculum Vitae

PERSONAL INFORMATION

Heidi Meyer

WORK EXPERIENCE

January 1993-June 2002

Head of department Viral Vaccines

Baxter Vaccines AG, Biomedical research center, Orth a.d. Donau (Austria)

Research and development with specific focus on the development, preclinical testing and production of viral vaccines as well as on virus safety aspects of biomedicinal products

July 2002-April 2016

Deputy head of section viral vaccines

Paul-Ehrlich-Institut (Germany)

Assessment of applications for marketing authorisation and variations for viral vaccines authorised on national or European level

Assessment of clinical trial applications

Involved in official batch release activities.

Collaboration with national and international bodies (e.g. WHO, EDQM, ECDC)

May 2016- Present

Head international cooperation / regulatory service

Paul-Ehrlich-Institut (Germany)

Regulatory support

Assessment of applications for marketing authorisation and variations for viral vaccines authorised on national or European level

EDUCATION AND TRAINING

September 1987- Present

PhD

Institute for Clinical and Molecular Virology, Friedrich-Alexander Universität Erlangen-Nuernberg (Germany)

Clinical and molecular virology, microbiology, biotechnology, infectious diseases

ADDITIONAL INFORMATION

Expertise

Clinical and molecular virology

Biotechnology and virus safety aspects

Infectious diseases

Publications

Meyer H, Bankier AT, Landini MP, Brown CM, Barrell BG, Ruger B, Mach M.

Identification and procaryotic expression of the gene coding for the highly immunogenic 28-kilodalton structural phosphoprotein (pp28) of human cytomegalovirus.

J Virol 1988 Jul; 62(7): 2243-2250.

Lehner R, Meyer H, Mach M.

Identification and characterization of a human cytomegalovirus gene coding for a membrane protein that is conserved among human herpesviruses.

J. Virol. 1989 Sep; 63(9): 3792-3800.

Meyer H, Masuho Y, Mach M.

The gp116 of the gp58/116 complex of human cytomegalovirus represents the amino-terminal part of the precursor molecule and contains a neutralizing epitope.

J Gen Virol. 1990 Oct; 71(Pt10) : 2443-2450.

Meyer H, Mach M.

The glycoprotein gp116 of human cytomegalovirus contains two antibody binding sites in close proximity.

J Cell Biochem 1991; suppl. 15E: 101.

Meyer H, Sundquist VA, Pereira L, Mach M.

Glycoprotein gp116 of human cytomegalovirus contains epitopes for strain-common and strain-specific antibodies.

J Gen Virol. 1992 Sep; 73(Pt9) : 2375-2383.

Barrett PN, Meyer H, Wachtel I, Eibl J, Dorner F.

Determination of the inactivation kinetics of hepatitis A virus in human plasma products using a simple TCID50 assay.

J Med Virol. 1996 May; 49(1): 1-6.

Barrett PN, Meyer H, Wachtel I, Eibl J, Dorner F.

Inactivation of hepatitis A virus in plasma products by vapor heating.

Transfusion. 1997 Feb; 37(2): 215-220.

Kamphuis E, Meyer H, Gopfert C, Schildger H, Hanschmann K-M, Kramer B, and Duchow K. Rabies Vaccines for Human Use: Potency Testing Without Mouse Challenge? Altex 29, Special Issue 2012, Proceedings of WC8

Kamphuis E, Hanschmann KM, Meyer H, Gopfert C, Kramer B, Cussler K. Potency estimation of vaccine batches remains unaffected by anesthesia for intracerebral injection. Biologicals. 2012 Nov;40(6):451-5.

Mentzer D, Meyer H, Keller-Stanislawski B. Safety and tolerability of monovalent measles and combined measles, mumps, rubella, and varicella vaccines. Bundesgesundheitsbl 2013 · 56:1253-1259

Projects

Memberships

Other Relevant Information

Patents:

Human cytomegalovirus structural phosphoprotein (pp28), its preparation and use

(EP0330051)

Method of Large Scale Production of Hepatitis A Virus

(USA 10/006,882; EU: 02792958.7-2405-EP0214012)

Method of Production of Purified Hepatitis A Virus Particles and Vaccine Preparation (USA 10/006,205, EU: 02792955.3-2402-EP0214008)